La cadena de opciones muestra datos clave de las opciones de acciones de Joint a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Joint..

Joint (NASDAQ:JYNT) Bolsa, Cadena de Opciones

Joint

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

IMAC Holdings sube más del 108% tras anunciar Ignite Proteomics. Conoce las acciones más destacadas en la negociación previa.

Acciones de IMAC Holdings se disparan un 108%; 20 acciones en movimiento en el premercado de EE.UU.

The Joint Corp

2025 Guidance The company provided the following guidance for 2025.
<ul>
<li>System-wide sales are expected to be between $550 million and $570 million, compared to $530.3 million in 2024.</li>
<li>System-wide comp sales for all clinics open 13 months or more are expected to be in the mid-single digits, compared to 4% in 2024.</li>
<li>Consolidated Adjusted EBITDA is expected to be between $10.0 and $11.5 million, compared to $11.4 million in 2024. The 2025 Consolidated Adjusted EBITDA estimate includes an adjustment of $4.4 million related to, among other things, stock-based compensation and depreciation and amortization. The company will factor in any additional impairment or restructuring charges related to the refranchising should they occur.</li>
<li>New franchised clinic openings, excluding the impact of refranchised clinics, are expected to be between 30 and 40, compared to 57 in 2024.</li>
</ul>

News

Guidance

The Joint Corp. Sees FY25 System-Wide Sales $550M-$570M

Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $0.01 by 1900 percent. This is a 76 percent increase over losses of $(0.75) per share from the same period last year. The company reported quarterly sales of $14.45 million which missed the analyst consensus estimate of $28.99 million by 50.17 percent. This is a 13.68 percent increase over sales of $12.71 million the same period last year.

Earnings

Earnings Misses

Joint Q4 EPS $(0.18) Misses $0.01 Estimate, Sales $14.45M Miss $28.99M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Advanced Flower Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFCG#NASDAQ">AFCG</a>) is likely to report quarterly earnings at $0.36 per share on revenue of $11.76 million. 
• Ballard Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDP#NASDAQ">BLDP</a>) is likely to report quarterly loss at $0.13 per share on revenue of $28.55 million. 
• Perma-Fix Envirn Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PESI#NASDAQ">PESI</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $15.80 million. 
• ZSPACE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZSPC#NASDAQ">ZSPC</a>) is expected to report quarterly loss at $0.09 per share on revenue of $9.61 million. 
• CION Invt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CION#NYSE">CION</a>) is likely to report quarterly earnings at $0.35 per share on revenue of $54.11 million. 
• Altisource Portfolio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPS#NASDAQ">ASPS</a>) is expected to report earnings for its fourth quarter. 
• US Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEG#NASDAQ">USEG</a>) is expected to report quarterly loss at $0.08 per share on revenue of $4.54 million. 
• Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $37.36 million. 
• G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) is likely to report quarterly earnings at $0.97 per share on revenue of $807.11 million. 
• Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) is projected to report earnings for its fourth quarter. 
• Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) is projected to report quarterly loss at $0.16 per share on revenue of $13.39 million. 
• Global X Guru Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GURU#NYSE">GURU</a>) is estimated to report quarterly loss at $0.05 per share on revenue of $8.67 million. 
• D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) is expected to report quarterly loss at $0.06 per share on revenue of $2.23 million. 
• Village Farms Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) is projected to report quarterly loss at $0.02 per share on revenue of $81.68 million. 
• Lifetime Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCUT#NASDAQ">LCUT</a>) is expected to report quarterly earnings at $0.43 per share on revenue of $204.70 million. 
• CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) is likely to report quarterly earnings at $0.22 per share on revenue of $27.99 million. 
• Blade Air Mobility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $50.53 million. 
• Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) is expected to report quarterly earnings at $1.50 per share on revenue of $10.26 billion. 
• Build-A-Bear Workshop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBW#NYSE">BBW</a>) is estimated to report quarterly earnings at $1.50 per share on revenue of $147.53 million. 
• Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) is estimated to report earnings for its fourth quarter. 
• Aveanna Healthcare Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAH#NASDAQ">AVAH</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $499.61 million. 
• Century Casinos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTY#NASDAQ">CNTY</a>) is projected to report quarterly loss at $0.49 per share on revenue of $142.21 million. 
• Ucloudlink Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCL#NASDAQ">UCL</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $25.15 million. 
• Futu Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>) is projected to report earnings for its fourth quarter. 
• Aurora Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JG#NASDAQ">JG</a>) is expected to report earnings for its fourth quarter. 
• Pharming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>) is likely to report quarterly earnings at $0.01 per share on revenue of $76.67 million. 
• Nyxoah (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYXH#NASDAQ">NYXH</a>) is likely to report quarterly loss at $0.47 per share on revenue of $2.67 million. 
• Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) is likely to report earnings for its fourth quarter. 
• Xunlei (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNET#NASDAQ">XNET</a>) is estimated to report earnings for its fourth quarter. 
• Acacia Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTG#NASDAQ">ACTG</a>) is likely to report quarterly loss at $0.07 per share on revenue of $47.75 million. 
• Duluth Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTH#NASDAQ">DLTH</a>) is estimated to report quarterly earnings at $0.11 per share on revenue of $252.86 million. 
• Weibo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WB#NASDAQ">WB</a>) is projected to report quarterly earnings at $0.39 per share on revenue of $451.76 million. 
• Sotherly Hotels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOHO#NASDAQ">SOHO</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $42.80 million. 
<h3>Companies Reporting After The Bell</h3>
• Wheaton Precious Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPM#NYSE">WPM</a>) is projected to report quarterly earnings at $0.43 per share on revenue of $394.49 million. 
• DocuSign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) is likely to report quarterly earnings at $0.85 per share on revenue of $761.31 million. 
• Purple Innovation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPL#NASDAQ">PRPL</a>) is expected to report quarterly loss at $0.08 per share on revenue of $130.60 million. 
• Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) is likely to report quarterly earnings at $1.82 per share on revenue of $1.63 billion. 
• Frequency Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEIM#NASDAQ">FEIM</a>) is expected to report earnings for its third quarter. 
• Shimmick (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) is likely to report quarterly loss at $0.35 per share on revenue of $118.90 million. 
• Transact Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TACT#NASDAQ">TACT</a>) is projected to report quarterly loss at $0.10 per share on revenue of $10.37 million. 
• Cellectis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLLS#NASDAQ">CLLS</a>) is projected to report quarterly loss at $0.21 per share on revenue of $9.09 million. 
• Bridger Aerospace Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAER#NASDAQ">BAER</a>) is expected to report earnings for its fourth quarter. 
• Mach Natural Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNR#NYSE">MNR</a>) is estimated to report quarterly earnings at $0.77 per share on revenue of $253.99 million. 
• Skillz (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKLZ#NYSE">SKLZ</a>) is expected to report earnings for its fourth quarter. 
• Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) is likely to report quarterly loss at $0.63 per share on revenue of $3.08 million. 
• Turtle Beach (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBCH#NASDAQ">TBCH</a>) is expected to report quarterly earnings at $1.21 per share on revenue of $161.36 million. 
• FiscalNote Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>) is expected to report quarterly loss at $0.04 per share on revenue of $29.02 million. 
• aTyr Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) is projected to report earnings for its fourth quarter. 
• Pangaea Logistics Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANL#NASDAQ">PANL</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $142.61 million. 
• PSQ Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSQH#NYSE">PSQH</a>) is projected to report quarterly loss at $0.42 per share on revenue of $7.70 million. 
• VAALCO Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGY#NYSE">EGY</a>) is likely to report quarterly earnings at $0.05 per share on revenue of $108.91 million. 
• Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) is expected to report quarterly loss at $0.18 per share on revenue of $12 thousand. 
• Vuzix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VUZI#NASDAQ">VUZI</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $2.77 million. 
• WM Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAPS#NASDAQ">MAPS</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $46.00 million. 
• Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is projected to report quarterly earnings at $0.33 per share on revenue of $250.17 million. 
• Zumiez (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZUMZ#NASDAQ">ZUMZ</a>) is estimated to report quarterly earnings at $0.76 per share on revenue of $276.46 million. 
• OPAL Fuels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPAL#NASDAQ">OPAL</a>) is likely to report quarterly earnings at $0.35 per share on revenue of $92.09 million. 
• Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) is expected to report quarterly loss at $0.14 per share on revenue of $30.77 million. 
• HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) is estimated to report earnings for its fourth quarter. 
• Karat Packaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>) is expected to report quarterly earnings at $0.36 per share on revenue of $102.27 million. 
• AuthID (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>) is expected to report earnings for its fourth quarter. 
• PLBY Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBY#NASDAQ">PLBY</a>) is likely to report quarterly loss at $0.11 per share on revenue of $14.30 million. 
• Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) is projected to report quarterly loss at $1.11 per share on revenue of $23.52 million. 
• Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $22.29 million. 
• Xponential Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPOF#NYSE">XPOF</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $81.42 million. 
• ZOMEDICA CORP COM (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZOM#AMEX">ZOM</a>) is likely to report quarterly loss at $0.01 per share on revenue of $8.10 million. 
• GrowGeneration (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) is projected to report quarterly loss at $0.11 per share on revenue of $42.21 million. 
• Emeren Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) is likely to report quarterly earnings at $0.08 per share on revenue of $40.13 million. 
• PagerDuty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $119.53 million. 
• EverCommerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVCM#NASDAQ">EVCM</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $170.48 million. 
• Drilling Tools Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTI#NASDAQ">DTI</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $36.08 million. 
• AlTi Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTI#NASDAQ">ALTI</a>) is projected to report quarterly earnings at $0.02 per share on revenue of $74.60 million. 
• Origin Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGN#NASDAQ">ORGN</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $9.08 million. 
• Heritage Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HGBL#NASDAQ">HGBL</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $12.30 million. 
• Rubrik (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) is likely to report quarterly loss at $0.39 per share on revenue of $232.91 million. 
• Adecoagro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGRO#NYSE">AGRO</a>) is expected to report quarterly earnings at $0.41 per share on revenue of $348.33 million. 
• ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) is projected to report earnings for its first quarter. 
• Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) is estimated to report quarterly earnings at $7.13 per share on revenue of $3.47 billion. 
• Portman Ridge Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTMN#NASDAQ">PTMN</a>) is expected to report quarterly earnings at $0.65 per share on revenue of $15.33 million. 
• Logan Ridge Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRFC#NASDAQ">LRFC</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $5.00 million. 
• Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $28.95 million. 
• BuzzFeed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZFD#NASDAQ">BZFD</a>) is likely to report earnings for its fourth quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACTG

AFCG

AGRO

AKBA

ALLO

ALTI

APYX

ASPS

ATYR

AUID

AVAH

BAER

BEAT

BLDE

BLDP

BLNK

BZFD

CCLD

CION

CLLS

CLRB

CNTY

DLTH

DOCU

EVCM

EVOK

FEIM

FUTU

GIII

GRWG

GURU

HGBL

LCUT

LRFC

MAPS

MCRB

NOTE

NYXH

OPAL

ORGN

PANL

PESI

PHAR

PLBY

PRPL

PSQH

PTMN

QBTS

QNRX

RBRK

RGNX

SHIM

SKLZ

SMTC

SOHO

TACT

TBCH

TTAN

ULTA

USEG

VERI

VUZI

XNET

XPOF

ZSPC

ZUMZ

Earnings Scheduled For March 13, 2025

Shares of F5, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) rose sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/news/earnings/25/01/43288953/f5-shares-rally-after-better-than-expected-q1-results">better-than-expected first-quarter financial results.</a>
F5 reported quarterly earnings of $3.84 per share, which beat the analyst consensus estimate of $3.36. Quarterly revenue clocked in at $766.49 million which beat the analyst consensus estimate of $715.41 million and is an increase over sales of $692.6 million from the same period last year.
F5 shares jumped 14.9% to $310.00 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Lucas GC Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCL#NASDAQ">LGCL</a>) gained 71.5% to $0.9812 in pre-market trading.</li>
<li>60 Degrees Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) rose 66.1% to $1.28 in pre-market trading after falling 11% on Tuesday. 60 Degrees Pharma received IRB approval of Phase II study to examine tafenoquine for chronic babesiosis.</li>
<li>Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) gained 37% to $1.85 in pre-market trading. Silexion Therapeutics shares jumped 133% on Tuesday after the company reported new preclinical data for SIL-204 showing significant tumor reduction in pancreatic cancer models.</li>
<li>The Joint Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) gained 32% to $14.90 in pre-market trading. The Joint Corp recently announced a year-over-year increase in patient visits.</li>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) gained 27.4% to $1.72 in pre-market trading. Faraday Future received $30 million of previously committed financing.</li>
<li>Nextracker Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) gained 20.5% to $47.75 in pre-market trading after the company reported better-than-expected third-quarter financial results and raised its FY25 GAAP EPS guidance.</li>
<li>Banzai International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNZI#NASDAQ">BNZI</a>) rose 18.4% to $1.48 in pre-market trading after falling 9% on Tuesday. Banzai International recently announced the acquisition of Act-On Software.</li>
<li>Centuri Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRI#NYSE">CTRI</a>) shares jumped 16.4% to $24.45 in pre-market trading after dipping around 10% on Tuesday.</li>
<li>Turning Point Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPB#NYSE">TPB</a>) rose 14.4% to $68.79 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Culp, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CULP#NYSE">CULP</a>) shares fell 41.9% to $3.00 in pre-market trading.</li>
<li>Crown LNG Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBS#NASDAQ">CGBS</a>) dipped 24.9% to $0.3650 in pre-market trading after falling 4% on Tuesday.</li>
<li>Manhattan Associates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) shares fell 23.4% to $225.92 in pre-market trading following soft FY25 guidance.</li>
<li>IMAC Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) declined 22.9% to $0.94 in pre-market trading following a 47% surge on Tuesday.</li>
<li>Haoxi Health Technology Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAO#NASDAQ">HAO</a>) fell 22.3% to $2.86 in today's pre-market trading after jumping more than 46% on Tuesday.</li>
<li>First Commonwealth Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCF#NYSE">FCF</a>) shares dipped 22.1% to $13.10 in pre-market trading following fourth-quarter results.</li>
<li>LendingClub Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) fell 21% to $13.30 in pre-market trading following worse-than-expected reported fourth-quarter EPS results.</li>
<li>Alerus Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRS#NASDAQ">ALRS</a>) shares tumbled 20.7% to $16.00 in pre-market trading after reporting fourth-quarter results.</li>
<li>Mineralys Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) fell 18.8% to $8.00 in pre-market trading.</li>
<li>Capital Clean Energy Carriers Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCEC#NASDAQ">CCEC</a>) fell 18.6% to $15.00 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43263799/wall-streets-most-accurate-analysts-spotlight-on-3-tech-telecom-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Tech &amp; Telecom Stocks Delivering High-Dividend Yields</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

ALRS

BNZI

CCEC

CGBS

CTRI

CULP

FFIE

FFIV

LGCL

MANH

MLYS

SLXN

SXTP

Why F5 Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket

Shares of IMAC Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) rose sharply in today's pre-market trading after the company announced it launched Ignite Proteomics, <a href="https://www.benzinga.com/quote/BACK">its new subsidiary</a>.
IMAC shares jumped 108.6% to $1.73 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Dunxin Financial Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXF#NYSE">DXF</a>) gained 110.6% to $16.32 in pre-market trading after dipping 73% on Monday.</li>
<li>Planet Image International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YIBO#NASDAQ">YIBO</a>) rose 85.7% to $5.72 in pre-market trading following a 43% surge on Monday.</li>
<li>ZK International Group Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZKIN#NASDAQ">ZKIN</a>) gained 47% to $0.9998 in pre-market trading after the company reported a year-over-year increase in FY24 EPS results.</li>
<li>Hepion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) gained 32.7% to $0.2191 in pre-market trading after falling 13% on Monday. Hepion Pharmaceuticals recently announced a $9 million public offering.</li>
<li>Pulmonx Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) gained 27.2% to $8.00 in pre-market trading.</li>
<li>JIADE Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) rose 26.1% to $1.11 in pre-market trading after gaining around 18% on Monday.</li>
<li>Unity Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNTY#NASDAQ">UNTY</a>) gained 23.7% to $59.99 in pre-market trading.</li>
<li>Concentra Group Holdings Parent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CON#NYSE">CON</a>) shares jumped 14.6% to $26.99 in pre-market trading. Concentra recently announced a 5.5% increase in preliminary fourth-quarter 2024 revenue.</li>
<li>Empire Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EP#NYSE">EP</a>) rose 8.2% to $6.50 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Evergreen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGR#NASDAQ">EVGR</a>) shares fell 58.3% to $5.00 in pre-market trading.</li>
<li>Greenlight Capital Re, Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLRE#NASDAQ">GLRE</a>) shares fell 49.1% to $7.00 in pre-market trading.</li>
<li>Actuate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTU#NASDAQ">ACTU</a>) dipped 41.1% to $6.00 in pre-market trading.</li>
<li>Prothena Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) declined 31.4% to $11.01 in pre-market trading.</li>
<li>The Joint Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) fell 27.3% to $8.10 in today's pre-market trading. The Joint Corp recently announced a year-over-year increase in patient visits.</li>
<li>Varex Imaging Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VREX#NASDAQ">VREX</a>) shares dipped 26% to $10.10 in pre-market trading. Varex Imaging will report unaudited financial results for the first quarter of fiscal year 2025 on Thursday, Feb. 6.</li>
<li>Champions Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSBR#NASDAQ">CSBR</a>) fell 22.2% to $9.10 in pre-market trading.</li>
<li>EVI Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVI#NYSE">EVI</a>) shares tumbled 13.1% to $16.20 in pre-market trading. EVI Industries recently announced plans to acquire Haiges Machinery.</li>
<li>Scholar Rock Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) fell 13% to $37.00 in pre-market trading.</li>
<li>Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) fell 9.6% to $11.81 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/01/43230206/jim-cramer-is-worried-about-this-consumer-cyclical-stock-7-yield-something-may-be-wrong-here">Jim Cramer Is Worried About This Consumer Cyclical Stock: 7% Yield? &#8216;Something May Be Wrong Here&#8217;</a></li>
</ul>

Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket

WIIM

The Joint Corp shares are trading higher after the company announced a year-over-year increase in patient visits.

2024 Full Year Operating Highlights
<ul>
<li>Performed 14.7 million patient visits, compared to 13.6 million in 2023.</li>
<li>Treated 957,000 new patients, compared to 932,000 in 2023.</li>
<li>Increased system-wide sales1&nbsp;9%, compared to 12% in 2023.</li>
<li>Delivered comp sales2&nbsp;of 4% on par with 4% in 2023.</li>
<li>Sold 46 franchise licenses, compared to 55 in 2023.</li>
<li>Expanded total clinic count to 967, up from 935 clinics at December 31, 2023.
<ul>
<li>Opened 57, refranchised 3, and closed 18 (including 3 relocations) for a total of 842 franchised clinics at December 31, 2024, compared to 800 at December 31, 2023.</li>
<li>Refranchised 3 and closed 7 (including three non-traditional corporate units on Airforce bases) for a total of 125 company-owned or managed clinics at December 31, 2024, compared to 135 at December 31, 2023.</li>
</ul>
</li>
</ul>

General

The Joint Corp Performed 14.7M Patient Visits In 2024, Compared To 13.6M In 2023

Roth MKM analyst George Kelly maintains Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) with a Buy and lowers the price target from $16 to $15.

Price Target

Analyst Ratings

Roth MKM Maintains Buy on Joint, Lowers Price Target to $15

Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.01 by 300 percent. This is a 180 percent increase over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $30.198 million which beat the analyst consensus estimate of $28.376 million by 6.42 percent. This is a 2.46 percent increase over sales of $29.474 million the same period last year.

Earnings Beats

Joint Q3 2024 Adj. EPS $0.04 Beats $0.01 Estimate, Sales $30.198M Beat $28.376M Estimate

Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) System-wide sales are expected to be between $525 million and $535 million.

Joint Corp. FY 2024 System-wide sales are expected to be between $525 million and $535 million.

Management

The Joint Corp Appoints Sanjiv Razdan As Its President And CEO, Effective Today; Peter Holt Resigns

<ul>
<li>System-wide comp sales for all clinics open 13 months or more are expected to be in the mid-single digits in 2024.</li>
<li>New franchised clinic openings, excluding the impact of refranchised clinics, are expected to be between 60 and 75, compared to 104 in 2023.</li>
</ul>

The Joint Corp Reiterates All Elements Of Its FY24 Guidance; Expects System-Wide Sales To Be $530M - $545M

Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.02) by 200 percent. The company reported quarterly sales of $30.261 million which beat the analyst consensus estimate of $29.397 million by 2.94 percent. This is a 3.26 percent increase over sales of $29.307 million the same period last year.

Joint Q2 2024 Adj. EPS $(0.06) Misses $(0.02) Estimate, Sales $30.261M Beat $29.397M Estimate

Quest Diagnostics (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>) has entered into a definitive agreement with OMERS to acquire LifeLabs, a prominent Canadian provider of community laboratory tests. The deal, valued at approximately CAN $1.35 billion ($985 million), underscores DGX&#39;s strategy to expand its footprint in Canada&#39;s healthcare diagnostics market.
By integrating LifeLabs into its operations, Quest Diagnostics aims to enhance the accessibility and quality of diagnostic services for Canadians.
Investors should note that OMERS, a jointly sponsored, defined benefit pension plan, purchased LifeLabs back in 2007.
<h3>Terms and Strategic Vision</h3>
Under the latest agreement, Quest Diagnostics will acquire 100% of LifeLabs&#39; equity, funding the transaction through cash and debt. The acquisition is expected to generate annual revenues of approximately CAN $970 million ($710 million) and will be slightly dilutive to Quest Diagnostics&#39; GAAP EPS due to amortization. However, it will be accretive to adjusted EPS within the first year after closing.
LifeLabs will retain its brand, headquarters and management, ensuring continuity in its operations while benefiting from Quest&#39;s expertise and innovations.
<h3>Synergy Benefits</h3>
The acquisition promises several synergy benefits. Quest Diagnostics&#39; extensive experience and resources will bolster LifeLabs&#39; service offerings. This includes enhanced online appointment scheduling and quicker patient service center processing. Additionally, Quest Diagnostics plans to accelerate LifeLabs&#39; data security measures, ensuring that Canadian patients&#39; health data remains secure and within the country.
Quest Diagnostics&#39; recent advancements in specialized testing for Alzheimer&#39;s disease, women&#39;s health, oncology and cardiometabolic health will also be integrated into LifeLabs&#39; services. This will provide Canadians with access to cutting-edge diagnostics, enhancing overall healthcare delivery.
<h3>Strengthening Collaboration</h3>
The five-year long-established relationship between Quest Diagnostics and LifeLabs, through the Global Diagnostic Network and reference testing agreements, sets a strong foundation for this acquisition. This existing collaboration has already facilitated the sharing of expertise and broadened testing access, which will be further amplified post-acquisition.
By leveraging Quest&#39;s innovations and LifeLabs&#39; established presence, the partnership aims to meet the growing healthcare needs of Canadians, driving improved health outcomes and service efficiency.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/2a/70342.jpg?v=1935716916" style="border-style:solid; border-width:1px" />
Image Source: Zacks Investment Research
<h3>Industry Prospects</h3>
According to an Insights 10 report, the clinical diagnostics market in Canada is poised for substantial growth. It is projected to rise from $3.9 billion in 2022 to $4.9 billion by 2030 at a CAGR of 3.1%. This growth is likely to be driven by increased awareness of early disease detection and treatment benefits, alongside significant government investments in diagnostic services. Key players such as LifeLabs, SickKids and Dynacare dominate the market, which is segmented by molecular diagnostics and end users. Government initiatives, like Bill C-17, further bolster the market&#39;s expansion by providing additional funding for healthcare improvements.
<h3>Share Price Performance</h3>
Year to date, shares of DGX have risen 2.2% compared with the industry&#39;s 5.7% growth.
<h3>Zacks Rank and Key Picks</h3>
Quest Diagnostics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Hims &amp; Hers Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hims#NYSE">HIMS</a>), The Joint Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jynt#NASDAQ">JYNT</a>) and Medpace Holdings (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/medp#NASDAQ">MEDP</a>). While Hims &amp; Hers and The Joint currently sport a Zacks Rank #1 (Strong Buy) each, Medpace Holdings carries a Zacks Rank #2 (Buy) at present.
The Hims &amp; Hers Heath stock has surged 130.5% in the past year. Estimates for the company&#39;s 2024 earnings have moved north by 5.6% to 19 cents per share in the past 30 days.
HIMS&#39; earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. In the last reported quarter, it posted an earnings surprise of a staggering 150%.
Estimates for The Joint&#39;s 2024 earnings per share have remained constant at 21 cents in the past 30 days. Shares of JYNT have surged 38.8% year to date against the industry&#39;s 5.3% decline.
In the last reported quarter, JYNT delivered an earnings surprise of 300%. It has a trailing four-quarter average earnings surprise of 18.75%.
Estimates for Medpace&#39;s 2024 EPS have remained unchanged at $11.29 in the past 30 days. Shares of the company have surged 70.1% in the past year compared with the industry&#39;s 4.6% growth.
MEDP&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%.
<a href="https://www.zacks.com/stock/news/2296967/quest-diagnostics-dgx-to-expand-in-canada-with-lifelabs-buyout?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2296967">To read this article on Zacks.com click here.</a>

Health Care

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MEDP

Quest Diagnostics to Expand in Canada With LifeLabs Buyout

Neuronetics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/stim#NASDAQ">STIM</a>) recently announced the nationwide launch of the Better Me Provider (BMP) program. The BMP program will be a part of the company&#39;s NeuroStar product line. The providers participating in the program are expected to maintain correct standards, developed in collaboration with a network of transcranial magnetic stimulation&nbsp;medical experts.
The latest development will help Neuronetics meet new standards and improve treatment accessibility within the mental health industry.
<h3>About BMP Program</h3>
Better Me Provider Program is an extensive commercial initiative to support practices committed to meeting patient care and responsiveness standards. These standards are developed in collaboration with TMS medical experts, ensuring prompt response times by a dedicated NeuroStar coordinator, who advises patients about the benefits of the entire course of NeuroStar treatment, along with optimizing websites and social media content to educate patients. It is designed to help people with major depressive disorder, obsessive-compulsive disorder, and anxious depression.
<h3>More on the News</h3>
In the initial days of the trial, the BMP program showed success by significantly increasing provider efficiency and responsiveness.
The trial result validated that the BMP program significantly accelerated patient engagement by swiftly addressing interested patients. Through advanced training of the providers and improved response time, the company is expecting to treat more patients in need of life-changing therapy.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/c6/70069.jpg?v=1098905618" /> 
Image Source: Zacks Investment Research
<h3>Industry Prospects</h3>
Per a report&nbsp;from Skyquest, the global Mental Health market was valued at $399.6 billion in 2022 and is expected to grow $544.6 billion by 2031, at a CAGR of 3.5% during the period. The primary factors influencing the global market include the increasing prevalence of mental health disorders worldwide and advancements in technology and research, which have led to the development of innovative treatment options. The growing awareness and acceptance of mental health issues also contribute to the market&#39;s growth.
Looking at the market potential, Neuronetics&#39; latest development is thoughtful and well-timed.
<h3>Other Notable Developments</h3>
Earlier this year, Neuronetics announced the FDA clearance of NeuroStar Advanced Therapy for usage as a supplement to treat MDD in adolescents aged between 15 years and 21 years. NeuroStar is the first and only FDA-approved transcranial magnetic stimulation treatment available for this age group.
In March 2024, Neuronetics entered into an expanded commercial partnership with Transformations Care Network (TCN), a mental health care provider. The company will supply new TMS equipment to TCN. This partnership marks a significant advancement in the field of mental health treatment, particularly for patients suffering from MDD and treatment-resistant depression.
<h3>Price Performance</h3>
In the past year, STIM&#39;s shares have lost 21.2% against the industry&#39;s 3.1% growth.
<h3>Zacks Rank and Key Picks</h3>
Neuronetics currently carries a Zacks Rank #3 (Hold).&nbsp;
Some better-ranked stocks in the broader medical space are Hims &amp; Hers Health, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hims#NYSE">HIMS</a>), The Joint Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jynt#NASDAQ">JYNT</a>) and Medpace Holdings (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/medp#NASDAQ">MEDP</a>). While Hims &amp; Hers and The Joint sport a Zacks Rank #1 (Strong Buy) each, Medpace Holdings carries a Zacks Rank #2 (Buy) at present.&nbsp;
The Hims &amp; Hers Heath stock has surged 135.1% in the past year. Estimates for the company&#39;s 2024 earnings have moved north by 5.6% to 19 cents per share in the past 30 days.
HIMS&#39; earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. In the last reported quarter, it posted an earnings surprise of a staggering 150%.
Estimates for The Joint&#39;s 2024 earnings per share have remained constant at 21 cents in the past 30 days. Shares of JYNT have surged 37.4% year to date against the industry&#39;s 3.6% decline.
In the last reported quarter, JYNT delivered an earnings surprise of 300%. It has a trailing four-quarter average earnings surprise of 18.75%.
Estimates for Medpace&#39;s 2024 EPS have remained unchanged at $11.29 in the past 30 days. Shares of the company have surged 70.4% in the past year compared with the industry&#39;s 5.3% growth.
MEDP&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%.
<a href="https://www.zacks.com/stock/news/2296194/neuronetics-stim-expands-neurostar-portfolio-with-new-launch?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2296194">To read this article on Zacks.com click here.</a>

Penny Stocks

STIM

Neuronetics Expands NeuroStar Portfolio With New Launch

B. Riley Securities analyst Jeff Van Sinderen maintains Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) with a Buy and raises the price target from $12 to $20.

B. Riley Securities Maintains Buy on Joint, Raises Price Target to $20

Joint shares are trading higher after the company reported better-than-expected Q1 financial results and reiterated FY23 system-wide sales guidance. Also, Roth MKM reiterated a Buy rating on the stock and raised its price target from $13 to $16.

Roth MKM analyst George Kelly reiterates Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) with a Buy and raises the price target from $13 to $16.

Reiteration

Roth MKM Reiterates Buy on Joint, Raises Price Target to $16

The Joint Corp. Reiterated Guidance, 2024 System-Wide Sales Expected To Be $530M-$545M

Joint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYNT#NASDAQ">JYNT</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.01) by 700 percent. This is a 62.5 percent decrease over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $29.722 million which beat the analyst consensus estimate of $29.591 million by 0.44 percent. This is a 5.02 percent increase over sales of $28.301 million the same period last year.

Joint Q1 2024 GAAP EPS $0.06 Beats $(0.01) Estimate, Sales $29.722M Beat $29.591M Estimate

Press Releases

The Joint Corp. Reports 2024 Operating Metrics

Small Cap

The Joint Chiropractic Takes the Top Spot Again as No. 1 in Chiropractic Services Franchises by Entrepreneur Magazine

The Joint Corp. to Host Conference Call on Thursday, March 13th to Discuss Fourth Quarter and Year-end 2024 Results

The Joint Chiropractic's Dr. Anthony Tran Named Franchisee of the Year by the International Franchise Association

The Joint Corp. to Participate in the 37th Annual Roth Conference

The Joint Corp. Names SVP Development

The Joint Corp. Reports Fourth Quarter and Year-end 2024 Financial Results

The Joint Chiropractic Establishes Major Scholarship at Northwestern Health Sciences University

The Joint Corp. to Host Conference Call on Thursday, May 8th to Discuss First Quarter 2025 Results

The Joint Chiropractic is Named the Official Chiropractic Partner of TCU Athletics

Comments

Joint

Joint (JYNT) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL